Milurit (Allopurinol)

Allopurinol is converted in the body to oxypurinol, which competitively inhibits the enzyme xanthine oxidase. This enzyme normally converts hypoxanthine and xanthine into uric acid; inhibition reduces uric acid production, helping to keep serum levels within the therapeutic range.

The appropriate dose of Milurit is determined by the prescribing clinician based on the patient’s renal function, severity of hyperuricemia, and specific indication. Dosage adjustments may be required for individuals with impaired kidney function or those receiving concomitant medications.

Safety data for allopurinol in pregnancy and lactation are limited. It should only be used when the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Milurit product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Allopurinol, the active ingredient in Milurit, is a first‑line xanthine oxidase inhibitor widely used for chronic uric acid management. Alternatives such as febuxostat also inhibit xanthine oxidase but differ in metabolic pathways and may have distinct safety profiles, especially in patients with cardiovascular disease.

Milurit should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, excessive heat and direct sunlight to maintain its stability throughout its shelf life.

Milurit is taken orally, usually with a full glass of water. It can be administered with or without food, but consistent timing each day helps maintain stable drug levels. Patients should follow the prescribing clinician’s instructions regarding dosing frequency.

Serious adverse reactions include severe skin disorders such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, hypersensitivity syndrome with fever and organ involvement, and bone‑marrow suppression. Prompt medical attention is required if any of these symptoms develop.

Milurit is contraindicated in patients with known hypersensitivity to allopurinol or any component of the formulation. Caution is also advised for individuals with severe renal impairment, active liver disease, or those taking medications that have major interactions, unless closely monitored by a healthcare professional.